2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOCompleted
In this trial the outcomes of an Ultrapro mesh after endoscopic hernia repair (TEP) will be compared with the outcomes of a heavyweight mesh (Prolene) after TEP hernia repair. The primary objective is to determine the effect of a lightweight mesh (…